排序方式: 共有37条查询结果,搜索用时 15 毫秒
1.
Objective To discuss the significance of serum IgE before and after inhale glucocorticoid treat-ment of children's asthma. Methods 520 children with asthma were seleceted from the outpatient. Different type of fluticasone propionate were given to different age groups: Aerosol type by a spacer in less than 5 years old,and in-halant (Seretide) 5 years and the above. The dosage was between 200 μg/day to 375 μg/day. IgE was tested before and 3 months after the treatment. Results Serum IgE decreased significantly in 3 months treatment [ from (496.12±24.75) kU/L to (390.71±18.71) kU/L] (t=7.337,P<0.01). The change of IgE was related to clinical effect and age. The level increased in those less than 3 years [(307.05±34.71)kU/L vs (483.09±41.78) kU/L] (t=2.963,P=0.004),but decreased between 4 to 5 years old group [(543.46±51.03) kU/L vs (316.93±29.30) kU/L] (t=3.368,P=0.000) ,and decreased between 6 to 14 years old group[ (586.30±37.19)kU/L vs (387.61±27.60) kU/L] (t=4.827,P=0.000). In fluticasone group IgE level changed from (468.91±32.81) kU/L to (359.03±22.79) kU/L after treatment (t=5.988,P<0.01),which decreased from (586.30±37.19) kU/L to (387.6±27.60) kU/L in Salmeterol group (t=4.827,P<0.01). In 260 cases of IgE below 300 kU/L 109 cases (41.92%,109/260) increased while in 260 cases of IgE above 300 kU/L,total IgE lev-el increased in 45 cases (16.15% ,45/260) after treatment,with statistical significance(χ<'2>=37.789,P=0.000). Conclusion Inhale glucocorticoid can make the level of IgE decreased. 相似文献
2.
吸入糖皮质激素对哮喘儿童血清IgE的影响 总被引:1,自引:1,他引:0
目的 探讨哮喘儿童吸入糖皮质激素(ICS)治疗前后血清总IgE的变化及意义.方法 哮喘儿童520例,均给予ICS治疗.≤3岁142例,4~5岁169例,均给予储雾罐吸入丙酸氟替卡松气雾剂治疗;6~14岁209例,选用沙美特罗替卡松粉吸入剂治疗;剂量为200~375μg/d.治疗前与治疗后3个月复查IgE.结果 520例患儿治疗前IgE为(496.12±24.75)kU/L,治疗后IgE为(390.71±18.71)kU/L,差异有统计学意义(t=7.337,P<0.01).≤3岁组治疗前IgE为(307.05±34.71)kU/L,治疗后IgE为(483.09±41.78)kU/L,差异有统计学意义(t=2.963,P=0.004);4~5岁组治疗前ISE为(543.46±51.03)kU/L,治疗后IgE为(316.93±29.30)kU/L,差异有统计学意义(t=3.368,P=0.000);6~14岁组治疗前IgE为(586.30±37.19)kU/L,治疗后IgE为(387.61±27.60)kU/L,差异有统计学意义(t=4.827,P=0.000).氟替卡松治疗组治疗前IgE为(468.91±32.81)kU/L,治疗后IgE为(359.03±22.79)kU/L,差异有统计学意义(t=5.988,P<0.01);沙美特罗替卡松治疗组治疗前IgE为(586.30±37.19)kU/L,治疗后IgE为(387.61±27.60)kU/L,差异有统计学意义(t=4.827,P<0.01).治疗前IgE≤300 kU/L 260例,109例(41.92%,109/260)治疗后IgE升高;>300 kU/L 260例,45例(16.15%,45/260)治疗后血清总IgE升高,差异有统计学意义(χ<'2>=37.789,P=0.000).结论 ICS使IgE下降,IgE的检测有利于哮喘患者诊治过程中的病情观察. 相似文献
3.
Objective To discuss the significance of serum IgE before and after inhale glucocorticoid treat-ment of children's asthma. Methods 520 children with asthma were seleceted from the outpatient. Different type of fluticasone propionate were given to different age groups: Aerosol type by a spacer in less than 5 years old,and in-halant (Seretide) 5 years and the above. The dosage was between 200 μg/day to 375 μg/day. IgE was tested before and 3 months after the treatment. Results Serum IgE decreased significantly in 3 months treatment [ from (496.12±24.75) kU/L to (390.71±18.71) kU/L] (t=7.337,P<0.01). The change of IgE was related to clinical effect and age. The level increased in those less than 3 years [(307.05±34.71)kU/L vs (483.09±41.78) kU/L] (t=2.963,P=0.004),but decreased between 4 to 5 years old group [(543.46±51.03) kU/L vs (316.93±29.30) kU/L] (t=3.368,P=0.000) ,and decreased between 6 to 14 years old group[ (586.30±37.19)kU/L vs (387.61±27.60) kU/L] (t=4.827,P=0.000). In fluticasone group IgE level changed from (468.91±32.81) kU/L to (359.03±22.79) kU/L after treatment (t=5.988,P<0.01),which decreased from (586.30±37.19) kU/L to (387.6±27.60) kU/L in Salmeterol group (t=4.827,P<0.01). In 260 cases of IgE below 300 kU/L 109 cases (41.92%,109/260) increased while in 260 cases of IgE above 300 kU/L,total IgE lev-el increased in 45 cases (16.15% ,45/260) after treatment,with statistical significance(χ<'2>=37.789,P=0.000). Conclusion Inhale glucocorticoid can make the level of IgE decreased. 相似文献
4.
5.
目的:长期吸入糖皮质激素是哮喘的首选治疗方法,但国内外对于年幼儿童长期吸入糖皮质激素治疗的安全性仍有争议,本研究旨在探讨支气管哮喘患儿吸入糖皮质激素对骨龄及生长发育的影响。方法:73例支气管哮喘患儿给予丙酸氟替卡松吸入治疗,剂量250 μg/d,3个月后减量1/3续用3个月,再减为125 μg/d续用6个月,治疗后观察疗效,治疗前后分别测量骨龄、身高、体重。结果:入选患儿治疗后身高、体重及RUS骨龄增长与正常儿童差异无统计学意义(P>0.05);体重指数(BMI)治疗前后差异无统计学意义(P>0.05);治疗前后C骨龄与年龄差值分别为-0.2(-0.6,0.8)岁、-0.5(-1.0、0.6)岁,治疗后明显比治疗前延迟(P<0.05)。结论:哮喘患儿吸入糖皮质激素治疗 1年对C骨龄发育有一定抑制作用,对RUS骨龄、身高、体重及BMI无明显影响;长期糖皮质激素治疗的患儿应监测生长发育状况。 相似文献
6.
Objective To discuss the significance of serum IgE before and after inhale glucocorticoid treat-ment of children's asthma. Methods 520 children with asthma were seleceted from the outpatient. Different type of fluticasone propionate were given to different age groups: Aerosol type by a spacer in less than 5 years old,and in-halant (Seretide) 5 years and the above. The dosage was between 200 μg/day to 375 μg/day. IgE was tested before and 3 months after the treatment. Results Serum IgE decreased significantly in 3 months treatment [ from (496.12±24.75) kU/L to (390.71±18.71) kU/L] (t=7.337,P<0.01). The change of IgE was related to clinical effect and age. The level increased in those less than 3 years [(307.05±34.71)kU/L vs (483.09±41.78) kU/L] (t=2.963,P=0.004),but decreased between 4 to 5 years old group [(543.46±51.03) kU/L vs (316.93±29.30) kU/L] (t=3.368,P=0.000) ,and decreased between 6 to 14 years old group[ (586.30±37.19)kU/L vs (387.61±27.60) kU/L] (t=4.827,P=0.000). In fluticasone group IgE level changed from (468.91±32.81) kU/L to (359.03±22.79) kU/L after treatment (t=5.988,P<0.01),which decreased from (586.30±37.19) kU/L to (387.6±27.60) kU/L in Salmeterol group (t=4.827,P<0.01). In 260 cases of IgE below 300 kU/L 109 cases (41.92%,109/260) increased while in 260 cases of IgE above 300 kU/L,total IgE lev-el increased in 45 cases (16.15% ,45/260) after treatment,with statistical significance(χ<'2>=37.789,P=0.000). Conclusion Inhale glucocorticoid can make the level of IgE decreased. 相似文献
7.
8.
目的探讨哮喘儿童吸入糖皮质激素(ICS)治疗前后血清总IgE的变化及意义。方法选择2005年12月-2007年11月本院儿童哮喘门诊哮喘患儿351例。诊断标准参照全国儿童哮喘协作组标准。随机分为对照组(118例),ICS组(233例)。对照组主要以非特异性免疫调节剂治疗为主。ICS组〈5岁(162例)患儿选用储雾罐吸入氟替卡松气雾剂(辅舒酮),≥5岁(71例)患儿选用沙美特罗替卡松粉吸入剂(舒利迭)。对照组与ICS组分别于治疗前和治疗3个月运用全自动过敏原定量分析仪测定其血清IgE,ICS组继续治疗至1a,复查测定其血清IgE水平。结果对照组治疗前及治疗3个月IgE水平分别为(360.14±34.43)ng/L、(385.07±32.36)ng/L(P〉0.05);ICS组治疗前、治疗3个月及1aIgE分别为(586.26±42.39)ng/L、(453.12±30.74)ng/L、(421.96±25.73)ng/L,治疗前与治疗3个月比较有显著差异(t=4.744P〈0.01),治疗3个月与治疗1a比较无明显差异(t=1.384P〉0.05)。ICS治疗3个月,辅舒酮治疗者(162例)中107例(66.05%)控制,舒利迭治疗者(71例)中52例(73.24%)控制,二组比较无明显差异(P〉0.05)。辅舒酮治疗者中126例(77.78%)IgE水平下降,舒利迭治疗者中43例(60.56%)IgE下降,二组比较差异有显著性意义(P〈0.01)。结论ICS氟替卡松治疗儿童哮喘中等剂量可使血清IgE下降,IgE的检测有利于哮喘患儿诊治过程中的体内变态反应状况的观察。IgE下降在哮喘急性期明显,缓解期下降缓慢。二种不同剂型的ICS均能有好的临床疗效,但在降低血清IgE水平方面,舒利迭则不及辅舒酮。 相似文献
9.
喂养干预食物蛋白过敏婴儿临床疗效观察 总被引:1,自引:0,他引:1
目的:氨基酸配方和大豆蛋白婴儿配方粉剂治疗食物蛋白过敏患儿疗效观察。方法:临床观察氨基酸配方和大豆蛋白婴儿配方治疗食物蛋白过敏患儿症状临床疗效指标及不良反应指标。结果:氨基酸配方和大豆蛋白配方粉剂喂养食物蛋白过敏婴儿12周能改善患儿过敏症状和满足婴儿的正常发育的营养需要;且未见明显代谢异常。结论:氨基酸配方和大豆蛋白配方粉剂能明显改善患儿过敏症;肠内营养粉和大豆蛋白配方粉剂可满足食物蛋白过敏婴儿的正常发育生长;经过12周临床观察,喂养干预患儿未见明显代谢异常。 相似文献
10.
目的 观察阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患儿潮气呼吸肺功能参数变化及其对多导睡眠图(PSG)结果的预测价值.方法 选择OSAHS患儿68例,经整夜的PSG监测,根据PSG结果,分为PSG(+)组53例和PSG(-)组15例,计算呼吸紊乱指数(AHI)、呼吸暂停指数(AI)、低通气指数(HI)、最低血氧饱和度(LSaO2);对所有患儿行日间潮气呼吸肺功能检测,统计各组潮气量(VT/kg)、呼吸频率(RR)、吸气时间(TI)、呼气时间(TE)、吸呼比(TI/TE)、达峰时间(TPEF)、达峰时间比(TPEF/TE)、达峰容量(VPEF)、达峰容量比(VPEF/VE)、峰流速(PIEF)及分段的用力呼气流量(FEF 25%、FEF 50%、FEF 75%).结果 PSG(+)组和PSG(-)组患儿VT/kg、TPEF、TPEF/TE、VPEF、VPEF/VE差异有统计学意义(P<0.01).PSG(+)组的VT/kg明显降低,而TPEF、TPEF/TE、VPEF、VPEF/VE明显升高,各指标治疗后有不同稃度改善.应用多元线性回归分析得出AHI的数值高低与VT/kg、TPEF、TPEF/TE、VPEF、VPEF/VE有相关关系.对PSG及肺功能两种检查方法行配对资料χ2检验示两种方法差异无统计学意义(χ2>=3.5,P>0.05).结论 可以考虑将潮气呼吸肺功能作为儿童OSAHS的重要辅助检查方法之一,尤其足PSG检查前的筛查及对PSG阳性结果的预测,以探讨简便经济的筛查方法. 相似文献